Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
NCT00460460
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
75
Enrollment
INDUSTRY
Sponsor class
Stopped
Study was terminated due to low enrollment
Conditions
Lymphoma
Interventions
DRUG:
AZD4877
Sponsor
AstraZeneca